When anti-angiogenic drugs are used in combination with programmed death-(ligand)1 (PD-[L]1) inhibitor, immune checkpoint activity is suppressed, and T-cell function is enhanced, leading to a stronger anti-tumor response (13, 14). Here, CD274 is linked to neoplasm.